🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million instances per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This medication, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval represents a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

As per findings published in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves two antibiotics. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Medical professionals directly involved have expressed hope. Having a one-pill regimen such as this is described as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.